Nordson Corporation (NDSN) FY2025 Earnings Quality Report

Grade: F — Major Red Flags

Framework: Schilit *Financial Shenanigans* + Beneish M-Score + forensic accounting principles

Data: SEC EDGAR 10-K (Filed December 17, 2025, FY ended October 31, 2025) + Yahoo Finance

Auditor: Ernst & Young LLP — Unqualified opinion (1 critical audit matter: valuation of goodwill). Auditor tenure: 69 years (since 1956).

One-line verdict: Nordson is a high-quality precision dispensing business that has become a serial acquirer — ARAG, Atrion, and most recently the divestiture of its medical contract manufacturing product line in Q4 2025. Revenue rose 3.8% to $2.79B on the strength of the Atrion acquisition (MFS +20.1% total growth but -3.1% organic), while IPS (the largest segment) was organically down 5.1%. Operating profit grew 5.6% to $711.7M with 55.2% gross margin — excellent profitability. Free cash flow of $661M is strong. But two screening checks fail: cash of $108M covers only 5% of total debt of $2.09B (C4), and goodwill+intangibles of $4.0B equal 131% of equity (D1). Plus two watch items (D3 other assets +51.2%, E1 FCF after acquisitions negative 2 of 3 years). The critical audit matter from E&Y is specifically "Valuation of Goodwill" — $3.30B of goodwill is a large amount for a $2.79B revenue business, and the CAM language is about whether the annual impairment test assumptions are reasonable. The WACC used for the Medical and Fluid Solutions reporting unit (9.5%) has FV excess of 132% over CV — solid cushion but not overwhelming for the largest goodwill concentration ($1.66B).

A Precision Dispensing Business Turned Serial Acquirer

Nordson operates three segments with distinct end markets:

Geographic mix: Americas 43.2%, Asia Pacific 30.9%, Europe 25.9%. "Sales outside the United States accounted for 66.9 percent of total sales in 2025, as compared to 66.6 percent in 2024."

Financial Performance: Acquisition-Driven Growth

From the MD&A consolidated results table:

Revenue growth decomposition: +3.8% total = -2.5% organic + +6.0% acquisitions/divestitures + +0.3% currency. The organic decline of 2.5% is the story — without the Atrion acquisition, revenue would have fallen.

Segment performance:

Gross margin was unchanged at 55.2% — a very strong figure for an industrial business, driven by the dispensing technology's high value-added content and the Medical products' premium pricing.

SG&A rose just 0.4% to $815.5M despite the full-year Atrion impact — this implies meaningful operating leverage. Per the MD&A: "the increase in selling and administrative expenses was primarily driven by the full-year impact of the Atrion acquisition, partially offset by lower non-recurring acquisition costs."

Interest expense rose 20.3% to $101M "reflects higher average debt levels compared to the prior year due to the funding of acquisitions." This is the cost of the Atrion deal.

Net income grew 3.7% to $484M; EPS grew 5.0% to $8.51 because of share repurchases.

Cash Flow: The Quality Signal

From the MD&A cash flow table:

Per the MD&A: "The improvement in working capital was principally driven by increases in accounts payable and customer advance payments. During 2025, the Company was able to utilize its strong cashflow generation to repurchase over $300 million in common shares, reduce debt outstanding by approximately $224 million, pay $179 million in dividends, and fund capital projects to drive organic growth."

CFFO/NI of 1.48 is excellent. The FY2025 acquisition cash outflow of only $28M (actually a net inflow from the Q4 divestiture) is much smaller than FY2024's $790M net outflow for Atrion — this is why FY2025 is "digesting the acquisition" rather than "making a new one."

Capital deployment in FY2025:

Against FCF of $661M, the company went slightly over FCF by using cash balance — consistent with the $7.5M cash decline to $108M.

Balance Sheet: Goodwill-Heavy After Acquisitions

The CAM disclosure quantifies goodwill precisely: "At October 31, 2025, the Company had $3,304,685 thousand of goodwill." Per the CAM table:

The 132% excess at MFS is the tightest cushion — $1.66B goodwill at the largest segment has the smallest FV-over-CV buffer. Per the MD&A: "Potential events or circumstances, such as a sustained downturn in global economies, could have a negative effect on estimated fair values." A 20-30% reduction in MFS fair value assumptions would breach the carrying value.

D1 fails: goodwill+intangibles ≈ $4.0B / equity ~$3.05B = 131%.

Debt structure: Per the MD&A: "We have a $1,150,000 unsecured multi-currency credit facility with a group of banks that provides for a term loan facility in the aggregate principal amount of $300,000, maturing in June 2026, and a multicurrency revolving credit facility in the aggregate principal amount of $850,000, maturing in June 2028. At October 31, 2025, we had $265,000 outstanding on the term loan facility and $135,000 outstanding on the revolving credit facility."

So $400M of the $2.09B debt is under the credit facility (term loan + revolver drawn). The remainder is senior notes and other debt. The term loan matures June 2026 — refinancing at current rates will be higher than the existing coupon.

Cash position per the MD&A: "Cash and cash equivalents decreased $7,510 in 2025 to $108,442 as of October 31, 2025 compared to $115,952 as of October 31, 2024. Approximately 71 percent of our consolidated cash and cash equivalents were held at various foreign subsidiaries as of October 31, 2025." So only ~$31M of cash is held domestically.

C4 fails: Cash $108M / Total debt $2,092M = 5%. This is the tightest cash-to-debt ratio of any of the 10 tickers in this batch. However, the MD&A notes: "available borrowings under our loan agreements and unused bank lines of credit, which totaled $935,151 as of October 31, 2025." The $935M of committed revolver capacity is the operational liquidity reserve.

The 18-Point Screening

Revenue Quality

Revenue quality is clean. AR declined while revenue grew — the opposite of any manipulation pattern. DSO improved by 4 days.

Expense Quality

Cash Flow Quality

Balance Sheet

D3 watch: Other assets growing 51% against 4% revenue growth is the most extreme in the 10-ticker batch. This could reflect the Atrion acquisition recognizing intangibles/other assets, or it could signal capitalization practices worth examining. The MD&A doesn't directly address this line, so the explanation isn't definitive.

Acquisition Risk

E1 watch: This captures the Atrion acquisition. In FY2024, net FCF after acquisitions was substantially negative due to the $790M Atrion cash outflow. In FY2025, the divestiture proceeds partially offset new investment. The pattern is "large deal followed by digestion year."

Manipulation Score

M-Score components: DSRI 0.949, GMI 1.002, AQI 1.012, SGI 1.038, DEPI 0.870, SGAI 0.968, TATA -0.040, LVGI 0.941. All components are benign. DEPI of 0.870 (below 1.0) indicates accelerating depreciation — consistent with the Atrion acquisition's PPE stepping up. LVGI 0.941 (below 1.0) shows leverage slightly declining YoY because of the $224M debt repayment. TATA at -0.04 is slightly negative — accruals are conservative.

Key Risks from the 10-K

1. Critical Audit Matter: Valuation of Goodwill

E&Y's CAM is specifically about goodwill impairment testing: "At October 31, 2025, the Company had $3,304,685 thousand of goodwill. As discussed in Note 6 to the consolidated financial statements, the Company evaluates the carrying amount of goodwill for impairment annually as of August 1... The Company performed a quantitative impairment test for all reporting units in fiscal 2025. As part of the quantitative impairment tests, the Company estimated the fair value of each reporting unit using a combination of valuation techniques including the discounted cash flow method, a form of the income approach, and the guideline public company method, a form of the market approach. Auditing management's annual goodwill impairment assessment relating to goodwill was complex due to the use of valuation methodologies in the determination of the estimated fair values of the reporting units."

E&Y has served as NDSN's auditor since 1956 (69 years).

The MD&A disclosure of FV/CV excess by reporting unit is unusually detailed — most companies don't disclose this granularity. The 132% excess at MFS is the tightest cushion, and the WACC of 9.5% means a roughly 300bp increase in the discount rate could push carrying value above fair value.

2. Atrion Integration

The medical products acquisition has driven much of the FY2024-2025 balance sheet changes. Per the MD&A: "the increase in selling and administrative expenses was primarily driven by the full-year impact of the Atrion acquisition." The divestiture of the contract manufacturing product line in Q4 2025 — per "the $12,545K divestiture and related charges" — suggests portfolio cleanup is ongoing. Integration risk continues into FY2026.

3. IPS Cyclicality

IPS fell 5.1% organically due to "declines in polymer processing and industrial coatings product lines." These are tied to global manufacturing capacity utilization and capital spending cycles. IPS is 47.7% of revenue and 37.1% EBITDA margin — the segment most exposed to industrial cyclicality.

4. Tariff and Trade Policy Exposure

The risk factors: "the current U.S. presidential administration has imposed and significantly increased tariffs on foreign imports into the United States, particularly from Canada, China and Mexico. In response, many foreign countries have implemented or increased tariffs on imports into their countries." With 66.9% of sales outside the US, Nordson has meaningful tariff exposure on both exports (retaliatory tariffs) and imports (input costs).

5. Foreign Currency

"A significant portion of our consolidated revenues in 2025 were generated in currencies other than the U.S. dollar, which is our reporting currency." The MD&A disclosed $9.6M in "net foreign currency losses and pension losses" in Other expense in 2025 — not material but meaningful at the margin.

6. Term Loan Maturity June 2026

$265M of the $300M term loan is outstanding and matures in June 2026. Refinancing at current rates will raise the blended cost of debt.

7. Cash Repatriation

"Approximately 71 percent of our consolidated cash and cash equivalents were held at various foreign subsidiaries as of October 31, 2025." Domestic cash is only ~$31M — the company depends heavily on operating cash generation and the revolver for domestic liquidity.

8. Economic Cyclicality

The risk factors: "A portion of our product sales is attributable to industries and markets, such as the electronics, polymer processing, agriculture and metal finishing industries, which historically have been cyclical and sensitive to relative changes in supply and demand and general economic conditions. The demand for our products depends, in part, on the general economic conditions of the industries or national economies of our customers."

Summary

Grade: F, but this is a high-quality business with a balance sheet stretched by recent M&A.

Nordson's operating fundamentals are excellent: 55.2% gross margin, 25.5% operating margin, CFFO/NI of 1.48, free cash flow of $661M, and 69 years of continuous audit relationship with Ernst & Young. The M-Score of -2.66 is comfortably clean. Revenue quality passes all three checks (A1, A2, A3), expense quality passes all four (B1, B2, B3, B4), and cash flow quality passes three of four (C1, C2, C3).

The F grade is mechanical: C4 fails at 5% cash-to-debt (the tightest in the 10-ticker batch) and D1 fails at 131% goodwill-to-equity. Both reflect the 2024 Atrion acquisition, which added ~$2B of debt and goodwill. Management has been methodically deleveraging — paying down $224M of debt in FY2025 while still funding $306M in buybacks and $179M in dividends — but the pace is slow relative to the debt burden.

The watch items are equally Atrion-related. D3 (other assets +51%) and E1 (negative FCF after acquisitions 2 of 3 years) both capture the acquisition's balance sheet footprint. The M-Score's clean reading of -2.66 reinforces that the accounting is not being manipulated — the screening failures are structural capital-allocation choices.

E&Y's critical audit matter on goodwill valuation is precisely targeted. The MD&A's disclosure of the MFS reporting unit at only 132% FV/CV excess signals that another downturn in medical end markets could put the Atrion goodwill at risk of impairment. The other two segments have much larger cushions (IPS 311%, ATS 205%).

For a business with this quality of operating profile, the F grade reflects capital structure, not operating concerns. Watch the June 2026 term loan refinancing and the organic performance of IPS (which needs to stabilize after a 5% decline year) as the leading indicators for FY2026.

**Disclaimer**: This report is based on Nordson Corporation's FY2025 10-K filed with SEC EDGAR. This is NOT investment advice.

Data: SEC EDGAR 10-K + Yahoo Finance

Auditor: Ernst & Young LLP (Unqualified opinion, 1 critical audit matter — valuation of goodwill). Auditor tenure: 69 years (since 1956).

Fiscal year ended: October 31, 2025